Improved assessment of axillary lymph node status with FAPI PET/CT led to restaging of nearly 71 percent of patients with breast cancer, according to new research presented at the SNMMI 2024 conference.
Can fibroblast activation protein inhibitor (FAPI) PET/CT have an impact in staging for women with newly diagnosed breast cancer?
For the study, which was presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers compared clinical TNM staging between FAPI PET/CT and 18F-FDG PET/CT, which is commonly utilized in breast cancer staging. The cohort was comprised of 121 women with breast cancer. According to the study, 53 women had 68Ga-FAPI-04 PET/CT, 68 study participants had A118F-FAPI-04 PET/CT and all patients had 18F-FDG PET/CT scans.
The researchers found that FAPI PET/CT, in comparison to TNM staging with 18F-FDG PET/CT, restaged 19.8 percent of patients (24/121). Assessment of axillary lymph node (ALN) status by FAPI PET/CT was a significant factor for 17 of 24 patients (70.8 percent) who had TNM restaging, according to the study authors.
New research presented at the SNMMI 2024 conference found that FAPI PET/CT, in comparison to TNM staging with 18F-FDG PET/CT, restaged 19.8 percent of patients (24/121) with newly diagnosed breast cancer,
Noting the challenges with 18F-FDG PET/CT with respect to reduced sensitivity in certain breast cancer subtypes and false positives with inflammatory breast lesions, the researchers said the study findings show that FAPI PET/CT can be a viable alternative.
“This study is significant as it has the potential to advance personalized treatment strategies for breast cancer patients,” noted lead study author Zhixin Hao, M.D., a nuclear medicine physician affiliated with Peking Union Medical College Hospital in Beijing, China. “FAPI PET/CT for the initial staging of breast cancer has the potential to reduce unnecessary treatments and improve patient outcomes.”
The researchers also pointed out that FAPI PET/CT down-staged 20.6 percent of women (7/34) with initial IIB staging andupstaged 21.7 percent of patients (10/46) with initial IIA staging.
“Patients with stage IIA (breast cancer) should be considered for systemic staging with FAPI PET/CT at the time of initial diagnosis,” emphasized Hao and colleagues.
Reference
1. Hao Z, Pan B, Yao R, Zhou Y, Sun Q, Huo L. FAPI versus 18F-FDG PET/CT for systemic staging of newly diagnosed breast cancer. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 11, 2024.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
Study Assesses Amyloid PET/MRI Combination in Detection of Alzheimer’s Disease
July 15th 2024Emerging research revealed that a machine learning combination of amyloid beta PET and structural MRI demonstrated an 89 percent AUC in differentiating between older healthy patients and those with Alzheimer’s disease.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.